SPEAKERS Welcome to the Development of Therapies for Celiac Disease Conference Daniel C. Adelman , MD Alvine Pharmaceuticals, Inc., USA Celiac Disease Center at Columbia University hosted by the Celiac Disease Center at Columbia University at the Faculty Armin Alaedini , PhD Columbia University Medical Center, USA House at Columbia University, New York City. Robert P. Anderson , BMedSc, MBChB, PhD ImmusanT, Inc., USA hosts the Carolina Arguelles Grande , MD Columbia University Medical Center, USA Celiac disease is very common, affecting about 1% of the population. Julio C. Bai , MD Hospital de Gastroenterología Current therapy is dietary; however, there is increasing interest in non- Dr. Carlos Bonorino Udaondo, Argentina dietary alternatives. This conference presents a unique opportunity Govind Bhagat , MD Columbia University Medical Center, USA Development of Therapies to bring together those interested in the development of non dietary Carlo Catassi , MD, MPH Università Politecnica delle Marche, Italy therapies for the disease. Edward J. Ciaccio , PhD Columbia University Medical Center, USA for Celiac Disease CONFERENCE Paul Ciclitira , MD, PhD King's College London, UK Shuttle service to the Faculty House at Columbia University and Ink48 Amy R. DeFelice , MD Columbia University Medical Center, USA Hotel will be available at the following times. Alessio Fasano , MD Massachusetts General Hospital, USA Peter H.R. Green , MD Columbia University Medical Center, USA March 20-21, 2014 Marios Hadjivassiliou , MD Royal Hallamshire Hospital, UK Date Pick Up Location Departure Time Faculty House at Columbia University Ivor D. Hill , MD, MB Nationwide Children's Hospital, USA Martin F. Kagnoff , MD University of California San Diego, USA 64 Morningside Drive Wednesday, March 19 Main entrance of Ink 48 Hotel 5:15 pm & 653 11th Avenue (at 48th Street) 5:30 pm Donald Kasarda , PhD United States Department of Agriculture, USA (Between 116th and 118th Streets) ___________________________________________________________________ Katri Kaukinen , MD, PhD University of Tampere, Finland New York, NY 10027 Wednesday, March 19 Faculty House at Columbia University 8:00 pm Sonia Kupfer , MD University of Chicago, USA 64 Morningside Drive Benjamin Lebwohl , MD, MS Columbia University Medical Center, USA Program (between 116th & 118th Streets) ___________________________________________________________________ Jessica J. Lee , MD, MMSc United States Food and Drug Administration, USA Daniel A. Leffler , MD, MS Beth Israel Deaconess Medical Center, USA Thursday, March 20 Main entrance of Ink 48 Hotel 6:45 am & Suzanne K. Lewis , MD Columbia University Medical Center, USA 653 11th Avenue (at 48th Street) 7:00 am ___________________________________________________________________ Edwin Liu , MD University of Colorado Denver, USA Thursday, March 20 Faculty House at Columbia University 7:30 pm Jonas F. Ludvigsson , MD, PhD Karolinska Institutet, Sweden 64 Morningside Drive Knut E.A. Lundin , MD, PhD University of Oslo, Norway (between 116th & 118th Streets) Markku Maki , MD, PhD University of Tampere, Finland ___________________________________________________________________ Maria Luisa Mearin , MD Leiden University Medical Centre, The Netherlands Friday, March 21 Main entrance of Ink 48 Hotel 6:45 am & Joachim W. Messing , PhD Rutgers University, USA 653 11th Avenue (at 48th Street) 7:30 am A scientific program designed for those interested in the development of ___________________________________________________________________ Chris J.J. Mulder , MD, PhD VU University Medical Center, The Netherlands Joseph A. Murray , MD Mayo Clinic, USA non-dietary therapies for celiac disease including physicians, scientists, Friday, March 21 Faculty House at Columbia University 8:00 pm 64 Morningside Drive Yotam Nisemblat , MSc, MBA BioLineRx Ltd., Israel industry (pharmaceutical, diagnostic, biotechnology and food & agriculture) (between 116th & 118th Streets) Owen A. O'Connor , MD, PhD Columbia University Medical Center, USA and investor/venture capitalists. Norelle Rizkalla Reilly , MD Columbia University Medical Center, USA Detlef Schuppan , MD, PhD Mainz University Medical Center, Germany Faculty House at Columbia University Jennifer A. Sealey Voyksner , PhD Immunogenics, LLC, USA 64 Morningside Drive (between 116th & 118th Streets) Ludvig M. Sollid , MD, PhD New York, NY 10027 Oslo University Hospital, Norway Reidun B. Stenberg , MD, PhD Orebro Universitet, Sweden Elena Verdú , MD, PhD McMaster University, Canada For further information, please contact Cynthia Beckman at Alain Vicari , DVM, PhD Calypso Biotech SA, Switzerland [email protected] • www.celiacdiseasecenter.org Robert H. Yolken , MD The Johns Hopkins University School of Medicine, USA ) r Wednesday, March 19 11:45 am – 12:05 pm Q&A 10:10 am – 10:25 am Is a vaccine feasible for celiac disease? o o 12:05 pm – 1:20 pm Lunch Robert Anderson - USA l 6:00 pm – 8:00 pm Registration (Ground Level - 1st Floor) F 10:25 am – 10:40 am BL-7010 A therapy for celiac disease 6:00 pm – 8:00 pm (Skyline, 4th Floor) Epidemiological factors d Opening Reception r Yotam Nisemblat - Israel Benjamin Lebwohl - USA (Moderator) 3 ( Thursday, March 20 10:40 am – 10:55 am Montelukast in celiac disease 1:20 pm – 1:40 pm Unfolding story of celiac disease risk factors M Sonia Kupfer - USA 7:00 am – 6:00 pm Registration (Ground Level - 1st Floor) A Benjamin Lebwohl - USA 10:55 am – 11:10 am Q&A R 7:00 am – 9:00 am Breakfast (Ground Level - 1st Floor) 1:50 pm – 2:10 pm PreventCD update G 11:10 am – 11:25 am Break 7:30 am – 8:30 am NACCSD : Executive Council Meeting O Maria Luisa Mearin - The Netherlands R What is the status of the therapies? (Ground Level - 1st Floor) 2:20 pm – 2:40 pm Results of a prospective study on infant nutrition and P 8:35 am Introduction Katri Kaukinen - Finland (Moderator) C risk of celiac disease I Peter HR Green - USA F Carlo Catassi - Italy 11:25 am – 11:40 am Probiotics, do they have any role of celiac disease I 8:40 am – 9:00 am Immune pathogenesis of celiac disease T 2:50 pm – 3:10 pm Pregnancy and child outcomes in celiac disease management? N Ludwig Sollid - Norway Jonas Ludvigsson - Sweden Julio Bai - Argentina E I 3:20 pm – 3:35 pm Break 11:45 am – 12:05 pm Elafin, what is its role in celiac disease C The immune response to wheat proteins S Paul Ciclitira - UK (Moderator) Important issues Elena Verdu - Canada 12:10 pm – 12:30 pm Glutenase therapy (DSM) 9:10 am – 9:25 am Nutritional quality of seed storage proteins Markku Maki - Finland (Moderator) Chris Mulder - The Netherlands Joachim Messing - USA 3:35 pm – 3:55 pm Screening in celiac disease in childhood, pros & cons 12:35 pm – 12:55 pm Gluten detection in the food chain 9:25 am – 9:40 am Wheat gluten and celiac disease - an evolutionary Jennifer Sealey-Voyksner - USA collision Ivor Hill & Edwin Liu - USA 4:05 pm – 4:25 pm Gluten and biopsy outcome, why is it important 2:55 pm – 1:15 pm Q&A Donald Kasarda - USA in drug trials? 1:15 pm – 2:15 pm Lunch 9:40 am – 9:55 am Immune response to non gluten proteins Markku Maki - Finland Armin Alaedini - USA Neuropsychiatric manifestations of celiac disease 4:35 pm – 5:35 pm NACCSD : General Assembly - Annual General Meeting 9:55 am – 10:10 am Immune response to glutenin and other grains in and gluten sensitivity (1st Floor) celiac disease Armin Alaedini - USA (Moderator) 5:30 pm – 7:30 pm Reception (Skyline, 4th Floor) Paul Ciclitira - UK 2:15 pm – 2:35 pm Antibodies to food antigens and serious psychiatric Friday, March 21 10:10 am – 10:25 am Wheat amylase-trypsin inhibitors: their role in celiac disorders disease and beyond. 7:00am – 6:00 pm Registration (1st Floor) Robert Yolken - USA Detlef Schuppan - Germany 7:00 am – 9:00 am Breakfast (Seminar Level, 2nd Floor) 2:45 pm – 3:05 pm Gluten ataxia: update on mechanism and prevalence 10:25 am – 10:45 am Q&A 7:30 am – 8:25 am NACCSD : Executive Council with National Support Marios Hadjivassiliou - UK Celiac disease, refractory celiac disease and Group Leaders (4th Floor) 3:15 pm – 3:30 pm Break lymphoma What is the status of the therapies? Non-celiac gluten sensitivity Govind Bhagat - USA (Moderator) Joseph Murray - USA (Moderator) Peter HR Green - USA (Moderator) 10:45 am – 11:00 am Neglected intraepithelial innate cells 8:30 am – 9:00 am Drug development in celiac disease: FDA perspective 4:00 pm – 4:20 pm Gluten sensitivity is common Govind Bhagat - USA Jessica Lee - United States Food & Drug Administration, USA Alessio Fasano - USA 11:00 am – 11:15 am Epigenic therapies for T-cell lymphomas 9:10 am – 9:30 am Measuring outcomes in celiac disease 4:30 pm – 4:50 pm Gluten sensitivity is uncommon Owen O'Connor - USA Daniel Leffler - USA Peter HR Green - USA 11:15 am – 11:30 am The dark side of the moon : managing refractory 9:30 am – 9:45 am Glutenase therapy for celiac disease 5:00 pm – 5:20 pm Gluten sensitivity, is it real? FODMAPs, etc. celiac disease Daniel Adelman - USA Knut Lundin - Norway Joseph Murray - USA 9:45 am – 10:00 am Larazotide : an update 5:30 pm – 5:50 pm Wrap-Up 11:30 am – 11:45 am Discovery and development of a new anti IL-15 Joseph Murray - USA Marty Kagnoff - USA antibody for type II refractory celiac disease therapy 10:00m – 10:10 pm Q&A 6:00 pm – 8:00 pm Closing Reception (Skyline, 4th Floor) Alain Vicari - Switzerland ) r Wednesday, March 19 2:50 pm – 3:15 pm Gluten sensitivity, is it real? FODMAP, etc 12:55 pm – 2:00 pm Lunch o o Knut Lundin - Norway l 6:00 pm – 8:00 pm Registration (Ground Level - 1st Floor) The